| Budget Amount *help |
¥41,990,000 (Direct Cost: ¥32,300,000、Indirect Cost: ¥9,690,000)
Fiscal Year 2021: ¥10,400,000 (Direct Cost: ¥8,000,000、Indirect Cost: ¥2,400,000)
Fiscal Year 2020: ¥11,180,000 (Direct Cost: ¥8,600,000、Indirect Cost: ¥2,580,000)
Fiscal Year 2019: ¥10,920,000 (Direct Cost: ¥8,400,000、Indirect Cost: ¥2,520,000)
Fiscal Year 2018: ¥9,490,000 (Direct Cost: ¥7,300,000、Indirect Cost: ¥2,190,000)
|
|---|
| Outline of Final Research Achievements |
We conducted experiments to induce differentiation from human induced pluripotent stem cells (iPS) into human hematopoietic stem cells and human thymus. During the four-year study period, we investigated various differentiation conditions for human hematopoietic stem cells and human thymus, and transplanted them into immunodeficient mice. However, human hematopoietic cells could not be detected even by transplantation of hematopoietic stem like cells differentiated from iPS. It did not reach the originally planned standardization of humanized mice.
On the other hand, the newly developed NOG-c-kitV831M (W41) mouse was found to be an immunodeficient mouse extremely useful as a recipient for human hematopoietic stem cell transplantation. That is, hematopoietic stem cell transplantation into NOG-W41 mice can engraft even a very small number of cells without X-ray irradiation compared to NOG mice, and human hematopoietic cells engrafted in NOG-W41 mice can be engrafted in NOG mice.
|
